Cardiac Conduction Conditions – A-fib, Sick Sinus Syndrome — Clinical Documentation Guide (2026)

🔍 Definition

Cardiac conduction conditions encompass a broad spectrum of electrical disturbances in the heart’s rhythm-generating and impulse-conducting system. For coding and CDI purposes, two primary conditions anchor this guide: atrial fibrillation (A-fib) and sick sinus syndrome (SSS), with extended coverage of AV blocks, bundle branch blocks, and related arrhythmias.

Atrial Fibrillation (A-fib / AF) is the most common sustained cardiac arrhythmia, characterized by chaotic, disorganized atrial electrical activity replacing normal sinus rhythm. The atria quiver rather than contract effectively, producing an irregular, often rapid ventricular response. According to the CDC, an estimated 12.1 million people in the United States will have A-fib by 2030. Per the American Heart Association, A-fib significantly raises stroke risk (5×) and heart failure risk, making accurate classification and documentation critically important for care management and risk adjustment.

Sick Sinus Syndrome (SSS), coded as I49.5, represents dysfunction of the sinoatrial (SA) node — the heart’s primary pacemaker. It encompasses sinus bradycardia, sinus arrest, sinoatrial exit block, and the classic bradycardia-tachycardia syndrome (alternating slow and fast rhythms). SSS often requires permanent pacemaker implantation and frequently coexists with A-fib.

AV blocks (I44.x), bundle branch blocks (I44.4–I45.x), and other arrhythmias (I47.x, I49.x) also fall within this coding family and are covered in the code set section below.

🗂️ Alternative Terminology

🩺 Signs & Symptoms

Clinical presentation varies considerably by arrhythmia type, ventricular rate, and underlying cardiac function. Documentation should reflect which symptoms drove the encounter.

Atrial Fibrillation / Flutter:

• Palpitations (most common complaint) — described as racing, fluttering, irregular heartbeat
• Dyspnea on exertion or at rest (especially with rapid ventricular response or reduced EF)
• Fatigue, exercise intolerance, generalized weakness
• Dizziness, lightheadedness, near-syncope
• Chest pain or pressure (angina-equivalent, demand ischemia)
• Syncope (less common; warrants additional evaluation)
• Heart failure exacerbation (tachycardia-induced cardiomyopathy)
• Stroke or TIA symptoms (embolic; priority clinical concern — document CHA₂DS₂-VASc)
• Asymptomatic — detected incidentally on ECG or pulse oximetry

Sick Sinus Syndrome:

• Symptomatic bradycardia: fatigue, dizziness, presyncope, syncope (most common presentation)
• Exercise intolerance and chronotropic incompetence (heart rate fails to rise with exertion)
• Palpitations during tachycardia phase (tachy-brady syndrome)
• Cognitive impairment, memory difficulty in elderly patients
• Sinus pauses detected on Holter or event monitor

🧭 Differential Diagnosis

📋 Clinical Indicators for Coders/CDI

Accurate code selection requires documentation of specific clinical details. The table below maps key indicators to their coding impact.

🦴 Anatomy & Pathophysiology

Normal Cardiac Conduction: The sinoatrial (SA) node, located in the right atrium, generates the electrical impulse that initiates each heartbeat at 60–100 bpm. The impulse travels through atrial tissue to the atrioventricular (AV) node, which provides the critical 0.1-second delay allowing atrial systole before ventricular filling. From the AV node, the impulse passes through the Bundle of His, dividing into the right bundle branch (RBB) and left bundle branch (LBB — with anterior and posterior fascicles), and terminates in the Purkinje fiber network that activates ventricular myocardium.

Atrial Fibrillation Pathophysiology: A-fib results from multiple simultaneous re-entrant wavelets in atrial tissue, driven by enhanced automaticity (often from pulmonary vein foci) and atrial structural/electrical remodeling. Key mechanisms per the 2023 ACC/AHA/ACCP/HRS A-fib Guideline include: (1) triggered activity from pulmonary vein sleeves; (2) re-entrant circuits perpetuated by atrial fibrosis; (3) autonomic nervous system modulation. The result is uncoordinated atrial contraction, stasis in the left atrial appendage (thrombus formation risk → stroke), and irregular conduction to the ventricles (irregular ventricular response). Persistent and longstanding persistent A-fib involve progressive atrial remodeling that makes cardioversion less effective over time.

Sick Sinus Syndrome Pathophysiology: SA node dysfunction typically results from fibrous replacement of pacemaker cells (age-related), ischemia, cardiomyopathy, infiltrative disease (amyloid, sarcoid), or medication effects (beta-blockers, calcium channel blockers, digoxin, antiarrhythmics). The SA node fails to generate impulses at adequate rates or to conduct them to surrounding atrial tissue, producing bradycardia, sinus pauses, or sinoatrial exit block. In tachy-brady syndrome, bursts of A-fib or atrial tachycardia alternate with prolonged sinus pauses upon termination (due to suppression of the dysfunctional SA node), causing syncope.

AV Block Mechanisms: First-degree block represents delayed conduction through the AV node (PR >200 ms); second-degree Mobitz I (Wenckebach) is a nodal phenomenon with progressive fatigue; Mobitz II involves below-the-bundle disease (His-Purkinje), indicating more severe, potentially unstable pathology. Third-degree (complete) AV block produces complete dissociation — the atria and ventricles beat independently. An escape rhythm (junctional at 40–60 bpm or ventricular at 20–40 bpm) maintains cardiac output but is insufficient for activity.

💊 Medication Impact / Treatment

Pharmacologic management directly influences coding through drug status codes, adverse effect coding (when drug-induced arrhythmia), and anticoagulation documentation requirements.

Rate Control (A-fib):

• Beta-blockers (metoprolol, carvedilol, atenolol) — first-line; code long-term use under Z79.899 if applicable
• Non-dihydropyridine calcium channel blockers (diltiazem, verapamil) — alternative rate control
• Digoxin — less preferred; toxic at narrow therapeutic window; digoxin toxicity = adverse effect T46.0x5A

Rhythm Control (A-fib / Flutter):

• Antiarrhythmic drugs: flecainide, propafenone (class IC, SVT/paroxysmal AF), amiodarone, dronedarone (class III), sotalol
• Drug-induced proarrhythmia (e.g., amiodarone-induced torsades) must be coded as adverse effect
• Electrical cardioversion (DCCV) — procedure code 92960 (external) or 92961 (internal)

Anticoagulation — CRITICAL for CDI Documentation:

• Warfarin (Coumadin) — Z79.01; requires INR monitoring; reversal agent: Vitamin K (J3430) or 4-factor PCC
• DOACs:
  • Apixaban (Eliquis) — Z79.02; reversal: andexanet alfa (Andexxa, J7169)
  • Rivaroxaban (Xarelto) — Z79.02; reversal: andexanet alfa (Andexxa, J7169)
  • Dabigatran (Pradaxa) — Z79.02; reversal: idarucizumab (Praxbind, J3490)
  • Edoxaban (Savaysa) — Z79.02

SSS / AV Block Management:

• Treat reversible causes: electrolyte correction, medication adjustment (hold rate-lowering drugs)
• Temporary transcutaneous or transvenous pacing for symptomatic bradycardia
• Permanent pacemaker implantation: most definitive treatment for SSS, complete AV block (I44.2), symptomatic Mobitz II (I44.1)
• Biventricular pacing (CRT) for A-fib with LBBB and reduced EF

Left Atrial Appendage Occlusion (Watchman): For patients who cannot tolerate long-term anticoagulation; reduces stroke risk by mechanically excluding the LAA (primary thrombus source in A-fib). CPT 33267–33273; Z95.818 post-implant.

Catheter Ablation:

• Pulmonary vein isolation (PVI) for paroxysmal/persistent A-fib — CPT 93656 (A-fib PVI), 93657 (additional ablation); post-ablation with restored sinus → Z86.79
• AVNRT ablation — CPT 93654; SVT ablation — CPT 93653
• CTI ablation for typical flutter — CPT 93655 or 93651

Preview ends here. The full guide continues with FY2026 ICD-10-CM code sets, CPT surgical coding, MS-DRG mapping, reimbursement guidance, CDI query templates, and an audit checklist — all available to CCO Members.

← Back to All Clinical Documentation Guides

📘 ICD-10-CM Guidelines (FY2026)

All codes are effective for discharges and encounters on or after October 1, 2025, per the CMS FY2026 ICD-10-CM release.

A-fib / Flutter Type Selection

The FY2026 ICD-10-CM Official Guidelines require that atrial fibrillation be coded to the most specific type documented:

• Paroxysmal (I48.0): Episodes that self-terminate, typically within 7 days. If cardioverted within 7 days, still paroxysmal. Must be documented by physician as “paroxysmal.”
• Persistent (I48.11, I48.19): Does not self-terminate; requires pharmacologic or electrical cardioversion. Duration >7 days but <12 months. Longstanding persistent = >12 months (I48.11) and the physician is still attempting rhythm control.
• Chronic / Permanent (I48.20, I48.21): Physician and patient have decided to accept A-fib — rhythm control strategies abandoned. Permanent (I48.21) is the preferred specific code when documented.
• Unspecified (I48.91): Use ONLY when type cannot be determined from the record. Querying for type is a priority CDI activity.

Atrial Flutter Distinction

Atrial flutter and A-fib may be documented together; both may be coded if both are present and treated at the same encounter per AHA Coding Clinic guidance. Typical flutter (I48.3) involves the cavotricuspid isthmus (CTI) — the ablation target. Atypical flutter (I48.4) does not use the CTI circuit.

Sick Sinus Syndrome (I49.5)

Code I49.5 covers the full SSS spectrum including: sinus bradycardia (when pathologic, not physiologic), sinus arrest, sinoatrial exit block, and bradycardia-tachycardia syndrome. When A-fib is documented with SSS (tachy-brady pattern), code both I49.5 and the appropriate I48.x code.

AV Blocks

Code to the highest degree of block documented. Second-degree AV block (I44.1) should be specified as Mobitz I or Mobitz II by the clinician when possible, though ICD-10-CM does not subdivide I44.1 further. Complete AV block (I44.2) is a distinct and more severe entity — always code specifically when documented.

Sequencing Rules

• When A-fib is the reason for admission, sequence I48.x as principal diagnosis.
• When A-fib is a complication of another condition (e.g., post-cardiac surgery A-fib), the underlying condition may sequence first; review guideline I.C.9 for cardiac postprocedural complications.
• For acute MI with new A-fib, sequence the MI as principal; A-fib as secondary per guideline convention.
• Code all CHA₂DS₂-VASc risk factors (HTN I10, DM E11.x, prior stroke/TIA I69.x/Z86.73, vascular disease I25.x) as additional diagnoses when documented and managed.
• Post-ablation: Z86.79 (personal history of A-fib) is appropriate ONLY when the condition is resolved and no longer being treated. If monitored or on anticoagulation, the active A-fib code should remain.

Z Codes and Status Codes

• Z95.0 — Cardiac pacemaker in situ (assign when a pacemaker is present and relevant to care)
• Z95.810 — AICD (automatic implantable cardioverter-defibrillator) in situ
• Z95.818 — Other cardiac and vascular implants in situ (Watchman, CRT, other devices)
• Z79.01 — Long-term (current) use of warfarin/Coumadin
• Z79.02 — Long-term (current) use of anticoagulants (DOACs: apixaban, rivaroxaban, dabigatran, edoxaban)
• Z86.79 — Personal history of other heart conditions (use for resolved/post-ablation A-fib)

🔢 ICD-10-CM Code Set (FY2026)

Atrial Fibrillation and Flutter (I48)

Sick Sinus Syndrome and Other Cardiac Arrhythmias (I49)

AV Blocks and Conduction Disorders (I44)

Other Conduction and Block Codes (I45)

Tachycardia and Paroxysmal Arrhythmias (I47)

Cardiac Arrest (I46)

Symptom Codes (Use Only Without Specific Diagnosis)

Status and Z Codes

🔎 Indexing

The ICD-10-CM Alphabetic Index provides multiple pathways to A-fib and conduction disorder codes. Key index entries per the FY2026 ICD-10-CM Tabular List and Alphabetic Index:

🏥 CPT (2026)

CPT codes are per the AMA CPT 2026 code set. All codes require appropriate medical necessity documentation.

Diagnostic / Monitoring Services

Pacemaker and ICD Evaluation/Programming

Electrophysiology Studies and Ablation

Pacemaker Implantation (Surgical)

ICD Implantation (Surgical)

Left Atrial Appendage Occlusion (Watchman)

Cardiac Catheterization (EP Context)

🧾 HCPCS (2026)

📚 AHA Coding Clinic (Recent Guidance)

The following summarizes relevant AHA Coding Clinic guidance applicable to cardiac conduction and A-fib coding. Always verify with the most current Coding Clinic issues for your fiscal year, as guidance evolves.

💰 HCC / Risk Adjustment (v28)

HCC (Hierarchical Condition Category) mapping under CMS-HCC Model v28 affects Medicare Advantage risk-adjusted payments. Accurate diagnosis coding is essential for appropriate RAF (Risk Adjustment Factor) capture.

✍️ CDI Query Templates

All queries below follow ACDIS/AHIMA compliant query standards: non-leading, multiple-choice options provided, clinical indicator cited.

🧑‍⚕️ Treatments (Clinical)

Clinical treatment pathways for A-fib and related conduction disorders — relevant for CDI specialists to understand what procedures and interventions drive documentation and coding needs.

Atrial Fibrillation Management

Per the 2023 ACC/AHA/ACCP/HRS Atrial Fibrillation Guideline, management focuses on four pillars:

1. Stroke prevention: CHA₂DS₂-VASc score-guided anticoagulation; DOACs preferred over warfarin for non-valvular A-fib (Class I recommendation); Watchman device for patients with contraindication to anticoagulation
2. Symptom management: Rate control vs. rhythm control decision based on symptoms, A-fib type, and patient goals
3. Risk factor modification: Weight loss, exercise, hypertension control, sleep apnea treatment (OSA documented? — additional code G47.33)
4. Comorbidity management: Heart failure, HTN, DM optimization

Rate Control: Target resting HR <110 bpm (lenient) or <80 bpm (strict, symptomatic patients). Beta-blockers, non-DHP CCBs, digoxin. AV node ablation + pacemaker as last resort (codes I44.2 + Z95.0 post-procedure).

Rhythm Control: Antiarrhythmic drugs (flecainide, propafenone for structurally normal heart; amiodarone, sotalol, dronedarone for structural disease). Electrical cardioversion (CPT 92960). Catheter ablation (CPT 93656/93657) — increasingly first-line for paroxysmal A-fib per recent trials (CABANA trial).

Sick Sinus Syndrome Treatment

• Definitive treatment: Permanent pacemaker implantation (DDD pacing preferred for SSS to maintain AV synchrony)
• Eliminate/minimize causative medications (beta-blockers, CCBs, amiodarone)
• Tachy-brady SSS: Pacemaker enables safe use of rate-controlling agents to manage tachycardia phase
• Concomitant A-fib management: anticoagulation per CHA₂DS₂-VASc

AV Block Treatment

• First-degree: Monitor; identify and treat reversible causes (medications, electrolytes, Lyme disease, myocarditis)
• Second-degree Mobitz I: Usually benign; pacemaker if symptomatic or progression risk
• Second-degree Mobitz II: High risk of progression to complete block; pacemaker indicated even if asymptomatic
• Complete (third-degree) AV block: Always requires pacemaker; temporary transcutaneous/transvenous pacing as bridge; dual-chamber (DDD) preferred when atrial activity reliable

Ventricular Arrhythmia / ICD Therapy

• Primary prevention ICD: EF ≤35% despite optimal medical therapy (OMT) ≥3 months (CPT 33249)
• Secondary prevention ICD: Survived VF or hemodynamically unstable VT (CPT 33249)
• CRT-D: EF ≤35% + LBBB ≥150ms + NYHA class II–IV HF (CPT 33249 + 33225)
• VT ablation: Recurrent ICD shocks or VT storm; catheter ablation (CPT 93652)

🎓 Patient Education / Summary

This section provides plain-language reference points to assist CDI specialists and coders in understanding patient-facing documentation and communication.

What Patients Are Told About A-fib

Patients with A-fib are typically educated that their heart is beating irregularly, and that this increases their risk of stroke — which is why most are placed on blood thinners. According to the American Heart Association patient education materials, patients learn to monitor for symptoms like palpitations, shortness of breath, and dizziness, and understand that “paroxysmal” means it comes and goes while “permanent” means it is always present.

Key patient education concepts relevant to CDI documentation review:

• “Your A-fib comes and goes on its own” → paroxysmal → I48.0
• “You need a cardioversion (shock) to get you back into rhythm” → persistent → I48.19
• “Your A-fib has been continuous for over a year” → longstanding persistent → I48.11
• “We’ve decided to just control your heart rate and accept the irregular rhythm” → permanent → I48.21
• “You had A-fib before, but your ablation fixed it” → history of A-fib → Z86.79

What Patients Are Told About Pacemakers

Patients with SSS or complete AV block who receive pacemakers are educated that the device sends small electrical signals to keep the heart from beating too slowly. Post-implant, they carry a device card identifying the make/model/settings — this can be a CDI source for Z95.0 documentation support.

Stroke Prevention Patient Language

Blood thinner education is critical. When patients say “I take Eliquis” → apixaban → Z79.02; “I take Coumadin and need INR checks” → warfarin → Z79.01. Patient’s self-reported medication history can prompt a CDI query if anticoagulation is not documented in the physician’s assessment.

Coding Summary for Quick Reference

Sources: CMS FY2026 ICD-10-CM · AMA CPT 2026 · 2023 ACC/AHA A-fib Guideline · CMS-HCC v28 Risk Adjustment · AHA Coding Clinic

About this Guide

This Clinical Documentation Guide is published by CCO Academy and is intended for credentialed coding, CDI, and clinical documentation professionals. Content is updated for FY2026 ICD-10-CM (effective October 1, 2025). All code assignments should be verified against the official ICD-10-CM Tabular List, AHA Coding Clinic, and applicable payer-specific policies. This guide does not constitute legal, medical, or compliance advice.

Last reviewed: April 2026 · Next scheduled review: October 2026 (FY2027 update)